- Home
- NWE vs RARE Comparison
NWE vs RARE Comparison
Compare NWE & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NWE
- RARE
- Stock Information
- Founded
- NWE 1923
- RARE 2010
- Country
- NWE United States
- RARE United States
- Employees
- NWE N/A
- RARE N/A
- Industry
- NWE Power Generation
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- NWE Utilities
- RARE Health Care
- Exchange
- NWE Nasdaq
- RARE Nasdaq
- Market Cap
- NWE 3.1B
- RARE 3.5B
- IPO Year
- NWE N/A
- RARE 2014
- Fundamental
- Price
- NWE $51.04
- RARE $36.68
- Analyst Decision
- NWE Buy
- RARE Strong Buy
- Analyst Count
- NWE 7
- RARE 15
- Target Price
- NWE $60.00
- RARE $90.53
- AVG Volume (30 Days)
- NWE 480.4K
- RARE 1.1M
- Earning Date
- NWE 07-29-2025
- RARE 07-31-2025
- Dividend Yield
- NWE 5.19%
- RARE N/A
- EPS Growth
- NWE 18.67
- RARE N/A
- EPS
- NWE 3.84
- RARE N/A
- Revenue
- NWE $1,505,186,000.00
- RARE $590,689,000.00
- Revenue This Year
- NWE $5.89
- RARE $18.94
- Revenue Next Year
- NWE $4.74
- RARE $28.93
- P/E Ratio
- NWE $13.24
- RARE N/A
- Revenue Growth
- NWE 4.31
- RARE 33.46
- 52 Week Low
- NWE $48.52
- RARE $29.59
- 52 Week High
- NWE $59.89
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- NWE 34.96
- RARE 51.86
- Support Level
- NWE $50.46
- RARE $36.03
- Resistance Level
- NWE $52.22
- RARE $37.74
- Average True Range (ATR)
- NWE 0.76
- RARE 1.46
- MACD
- NWE 0.03
- RARE -0.01
- Stochastic Oscillator
- NWE 14.18
- RARE 26.56
About NWE NorthWestern Energy Group Inc.
NorthWestern Energy Group Inc provides electricity and natural gas services in the Upper Midwest and Northwest of the U.S. in the states of Montana, South Dakota, Nebraska, and Yellowstone National Park. The company's primary segments include Electric utility operations, which include the generation, purchase, transmission, and distribution of electricity, and Natural Gas utility operations, which include the production, purchase, transmission, storage, and distribution of natural gas. The company uses thermal, wind, hydro, or renewable energy in varying quantities, depending on the location of the facilities, to generate power. The company derives the majority of its revenue from the Electric utility operations segment.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.